Directors buying shortly after a massive ATM filing signals confidence that management views the current market cap as undervalued despite the massive dilution overhang. However, the $100M ATM overhanging the stock could pressure the float for months. Monitor subsequent insider activity and any Form 4 filings, continued buying by C-suite executives would be a stronger signal than these two director purchases.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 27 $0.5860entry
- T+1 · 6mo ago +26.28%α +25.73% · $0.7400
- T+5 · 6mo ago +38.91%α +37.70% · $0.8140
- T+20 · 5mo ago +174.74%α +176.65% · $1.61
- T+60 · 3mo ago +15.41%α +13.53% · $0.6763
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two directors at Outlook Therapeutics made open-market purchases totaling ~$179K on May 26, 2026, just 13 days after the company filed an at-the-market (ATM) offering agreement for up to $100M in common stock. Director Kurt J. Hilzinger bought 400,000 shares ($177K) and Director Randy H. Thurman bought 5,000 shares ($2K). The purchases represent ~0.37% of the company's $48M market cap, a notable insider vote of confidence given the massive dilution overhang from the recently disclosed ATM facility.
Key Financial Metrics
Key Facts
- Director Kurt J. Hilzinger purchased 400,000 shares at ~$0.44/share for $177K on 2026-05-26
- Director Randy H. Thurman purchased 5,000 shares at ~$0.43/share for $2K on 2026-05-26
- Total open-market insider purchases: ~$179K, representing ~0.37% of $48M market cap
- Purchases occurred 13 days after filing an ATM offering agreement for up to $100M in common stock (filed 2026-05-13)
- Stock closed at $0.2425 on 2026-05-12 prior to ATM filing; purchases at ~$0.44 suggest a more than 80% appreciation in two weeks
- No insider sales were detected in this cluster window
Financial Impact
~$179K in insider purchases, or ~0.37% of market cap
Risk Factors
- ATM facility allows sales up to $100M, ~208% of current market cap, creating severe potential dilution
- Only non-C-suite directors purchased; CEO/CFO have not bought and may have sold via ATM
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-OTLK-1779909681916 |
Track record
37 reports on OTLK
12 of 22 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 17 of 22 went positive at some point.
Filters
- Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
- Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
- Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
- Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
- Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers